RT Journal Article
SR Electronic
T1 Multivariate analysis of the effectiveness of bedaquiline-containing chemotherapy regimens in previously treated XDR TB patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1597
DO 10.1183/13993003.congress-2020.1597
VO 56
IS suppl 64
A1 Nataliya Stavitskaya
A1 Sergey Smerdin
A1 Dmitriy Kudlay
A1 Nataliya Doktorova
A1 Osiet Tlif
A1 Tatyana Petrenko
A1 Tatiana Kolpakova
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/1597.abstract
AB Method: Due to the widespread increase of XDR TB and the lack of choice of effective drugs, chemotherapy of these patients is a serious problem. The efficacy of treatment of XDR TB patients ranges from 29 to 33%.Purpose: Evaluation of therapeutic effectiveness of bedaquiline combined with second-line and other antibiotics in previously treated XDR-TB patients.Methods: 40 XDR-TB, CV + patients with massive bacterial excretion (aged from 22 to 74 yrs) previously ineffectively treated with 2nd-line drugs were observed. Young men prevailed, weighed down by alcohol, drug and tobacco addiction, HIV infection. Most patients had a low adherence to treatment. The course of Bq treatment was carried out in combination with anti-TB antibiotics according to the drug sensitivity test. Evaluation of the treatment effectiveness was performed using multivariate logistic regression analysis.Results: Bacteriological conversion and CV closure were achieved in 45% of cases. 12.5% of cases remained smear positive and 17.5 % died due to TB. Bq treatment did not require cessation of the drug intake. Testing of patients of different age revealed that duration of Bq treatment is a significant predictor of TB outcome in young people (p = 0.03); the presence of moxifloxacin or linezolid were also significant (p = 0.02 or 0.04 respectively).Conclusion: High effectiveness and good tolerance of Bq indicates to the necessity of the drug in the treatment of previously treated XDR TB patients. The high effectiveness of the bedaquiline-containing regimen depends on the presence of moxifloxacin and linezolid in the regimen.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1597.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).